AR034900A1 - Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica - Google Patents
Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad eficaInfo
- Publication number
- AR034900A1 AR034900A1 ARP020102810A ARP020102810A AR034900A1 AR 034900 A1 AR034900 A1 AR 034900A1 AR P020102810 A ARP020102810 A AR P020102810A AR P020102810 A ARP020102810 A AR P020102810A AR 034900 A1 AR034900 A1 AR 034900A1
- Authority
- AR
- Argentina
- Prior art keywords
- effective amount
- pde4 inhibitor
- composition
- separately
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Uso de una cantidad eficaz de un inhibidor de PDE4 y un agente anticolinérgico, bien en forma combinada sola o por separado, para la fabricación de composiciones farmacéuticas para la profilaxis, tratamiento o reducción de los empeoramientos asociados con una enfermedad pulmonar. Una composición para la profilaxis, tratamiento o reducción de los empeoramientos asociados a una enfermedad pulmonar, que comprende una cantidad eficaz de un inhibidor de PDE4, una cantidad eficaz de un agente anticolinérgico y un excipiente farmacéuticamente aceptable. Un método para preparar dichas composiciones que comprende mezclar una cantidad eficaz de un inhibidor de PDE4 y un agente anticolinérgico con un excipiente farmacéuticamente aceptable. Uso de una composición que comprende una cantidad eficaz de un inhibidor de PDE4, una cantidad eficaz de un agente anticolinérgico y un excipiente farmacéuticamente aceptable para la fabricación de un medicamento para la profilaxis, tratamiento o reducción de los empeoramientos asociados con una enfermedad pulmonar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0118373.0A GB0118373D0 (en) | 2001-07-27 | 2001-07-27 | Novel therapeutic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034900A1 true AR034900A1 (es) | 2004-03-24 |
Family
ID=9919332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102810A AR034900A1 (es) | 2001-07-27 | 2002-07-25 | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040180918A1 (es) |
| EP (1) | EP1411914A2 (es) |
| JP (1) | JP2004538302A (es) |
| KR (1) | KR20040029384A (es) |
| CN (1) | CN1551763A (es) |
| AR (1) | AR034900A1 (es) |
| BR (1) | BR0211450A (es) |
| CA (1) | CA2455520A1 (es) |
| CO (1) | CO5550426A2 (es) |
| GB (1) | GB0118373D0 (es) |
| HU (1) | HUP0401614A2 (es) |
| IL (1) | IL160017A0 (es) |
| MX (1) | MXPA04000793A (es) |
| NO (1) | NO20040353L (es) |
| PL (1) | PL368585A1 (es) |
| RU (1) | RU2004105865A (es) |
| WO (1) | WO2003011274A2 (es) |
| ZA (1) | ZA200400410B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| DE602004011494T2 (de) * | 2003-03-28 | 2009-01-22 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
| MXPA05010161A (es) * | 2003-03-28 | 2005-11-16 | Altana Pharma Ag | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| EP1504756A1 (en) * | 2003-08-06 | 2005-02-09 | Kyowa Hakko Kogyo Co., Ltd | Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| ES2413011T3 (es) | 2004-02-06 | 2013-07-15 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
| AU2005210086A1 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| NZ548301A (en) * | 2004-02-06 | 2010-07-30 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| WO2005102344A1 (ja) * | 2004-04-27 | 2005-11-03 | Kyowa Hakko Kogyo Co., Ltd. | 医薬組成物 |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| JP4991693B2 (ja) | 2005-03-16 | 2012-08-01 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤 |
| GB0521563D0 (en) | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
| DK1971369T3 (da) | 2005-12-21 | 2009-11-16 | Meda Pharma Gmbh & Co Kg | Kombination af R,R-glycopyrrolat, rolipram og budesonid til behandling af inflammatoriske sygdomme |
| WO2008015416A1 (en) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| EP2131834A2 (en) * | 2007-04-11 | 2009-12-16 | Alcon Research, Ltd. | Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| KR20110100679A (ko) | 2009-01-13 | 2011-09-14 | 글락소 그룹 리미티드 | Ｓｙｋ 키나아제의 억제제로서 피리미딘카르복사미드 유도체 |
| EP2482798A1 (en) * | 2009-10-01 | 2012-08-08 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
| WO2012025473A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
| WO2012025474A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Indazole compounds |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| PE20151332A1 (es) | 2013-02-19 | 2015-09-20 | Pfizer | Compuestos de azabencimidazol |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| WO2016020786A1 (en) | 2014-08-06 | 2016-02-11 | Pfizer Inc. | Imidazopyridazine compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
| DE60110205T2 (de) * | 2000-01-31 | 2006-01-26 | Pfizer Products Inc., Groton | Nicotinamide benzoanellierte-heterocyclische derivate als selektive inhibitoren der pde4 isoenzyme |
| ATE347557T1 (de) * | 2000-03-23 | 2006-12-15 | Takeda Pharmaceutical | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
| US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| AR029984A1 (es) * | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
| IL156558A0 (en) * | 2000-12-28 | 2004-01-04 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
-
2001
- 2001-07-27 GB GBGB0118373.0A patent/GB0118373D0/en not_active Ceased
-
2002
- 2002-07-25 MX MXPA04000793A patent/MXPA04000793A/es not_active Application Discontinuation
- 2002-07-25 KR KR10-2004-7001218A patent/KR20040029384A/ko not_active Application Discontinuation
- 2002-07-25 CA CA002455520A patent/CA2455520A1/en not_active Abandoned
- 2002-07-25 AR ARP020102810A patent/AR034900A1/es unknown
- 2002-07-25 WO PCT/EP2002/008322 patent/WO2003011274A2/en not_active Application Discontinuation
- 2002-07-25 CN CNA028173961A patent/CN1551763A/zh active Pending
- 2002-07-25 JP JP2003516505A patent/JP2004538302A/ja active Pending
- 2002-07-25 PL PL02368585A patent/PL368585A1/xx not_active Application Discontinuation
- 2002-07-25 HU HU0401614A patent/HUP0401614A2/hu unknown
- 2002-07-25 US US10/484,292 patent/US20040180918A1/en not_active Abandoned
- 2002-07-25 IL IL16001702A patent/IL160017A0/xx unknown
- 2002-07-25 RU RU2004105865/14A patent/RU2004105865A/ru not_active Application Discontinuation
- 2002-07-25 EP EP02754939A patent/EP1411914A2/en not_active Withdrawn
- 2002-07-25 BR BR0211450-0A patent/BR0211450A/pt not_active IP Right Cessation
-
2004
- 2004-01-20 ZA ZA200400410A patent/ZA200400410B/en unknown
- 2004-01-26 NO NO20040353A patent/NO20040353L/no not_active Application Discontinuation
- 2004-01-27 CO CO04005900A patent/CO5550426A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455520A1 (en) | 2003-02-13 |
| EP1411914A2 (en) | 2004-04-28 |
| BR0211450A (pt) | 2004-07-20 |
| KR20040029384A (ko) | 2004-04-06 |
| MXPA04000793A (es) | 2004-05-21 |
| NO20040353L (no) | 2004-03-26 |
| ZA200400410B (en) | 2004-10-13 |
| CO5550426A2 (es) | 2005-08-31 |
| HUP0401614A2 (hu) | 2004-11-29 |
| PL368585A1 (en) | 2005-04-04 |
| WO2003011274A3 (en) | 2003-09-18 |
| IL160017A0 (en) | 2004-06-20 |
| WO2003011274A2 (en) | 2003-02-13 |
| GB0118373D0 (en) | 2001-09-19 |
| JP2004538302A (ja) | 2004-12-24 |
| CN1551763A (zh) | 2004-12-01 |
| US20040180918A1 (en) | 2004-09-16 |
| RU2004105865A (ru) | 2005-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| GB0008269D0 (en) | Combination chemotherapy | |
| BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
| UY28509A1 (es) | Formas de dosificacion de azitromicina con efectos secundarios reducidos | |
| BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
| BR0112962B1 (pt) | Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos | |
| AR028959A1 (es) | Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares | |
| BRPI0409742A (pt) | uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica | |
| AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
| PL1680128T3 (pl) | Heksafosforan mio-inozytolu do stosowania miejscowego | |
| BRPI0606528A8 (pt) | composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma | |
| AR028986A1 (es) | USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| AR047480A1 (es) | Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion | |
| PT1220676E (pt) | Prevencao do cancro colorrectal | |
| SE0000303D0 (sv) | Novel compounds | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
| BR0206087A (pt) | Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias | |
| CO5261534A1 (es) | Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales | |
| BR0210063A (pt) | Composição estável e uso da mesma | |
| MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. | |
| BR0313305A (pt) | Agente analgésico para indivìduos recém-nascidos ou fetais | |
| AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |